Search Results - "Welz, Julia"

Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience by Moubarak, Malak, Harter, Philipp, Ataseven, Beyhan, Traut, Alexander, Welz, Julia, Baert, Thais, Heitz, Florian

“…•Real-life data support prospective evidence that 2nd PARPi therapy can be beneficial.•Patients who do not meet OREO criteria might also benefit from a PARPi…”
Get full text

Impact of hormone-associated resistance to activated protein C on the thrombotic potential of oral contraceptives: a prospective observational study by Rühl, Heiko, Schröder, Lars, Müller, Jens, Sukhitashvili, Shorena, Welz, Julia, Kuhn, Walther C, Oldenburg, Johannes, Rudlowski, Christian, Pötzsch, Bernd

“…The increased thrombotic risk of oral contraceptives (OC) has been attributed to various alterations of the hemostatic system, including acquired resistance to…”
Get full text

First results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer by Grabowski, Jacek P., Pietzke, Lea-Jean, Harter, Philipp, Heitz, Florian, Braicu, Elena Ioana, Arndt, Tjadina, Welz, Julia, Sehouli, Jalid

“…e17550 Background: Low-grade serous ovarian cancer (LGSOC), a rare ovarian malignancy, exhibits a very limited responsiveness to chemotherapy. There is a…”
Get full text

Low anterior resection syndrome and its impact on quality of life of ovarian carcinoma patients: A prospective longitudinal study by Imterat, Majdi, Gebers, Gudrun, Heitz, Florian, Schneider, Stephanie, Ehmann, Sarah, Welz, Julia, du Bois, Andreas, Traut, Alexander, Walz, Martin K, Concin, Nicole, Harter, Philipp, Ataseven, Beyhan

“…Bowel dysfunction is frequently reported in patients with ovarian carcinoma (OC). Our aim was to evaluate the incidence of low anterior resection syndrome…”
Get full text

Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy For Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient Tumors by Slomovitz, Brian M, Cibula, David, Lv, Weiguo, Ortaç, Fırat, Hietanen, Sakari, Backes, Floor, Kikuchi, Akira, Lorusso, Domenica, Dańska-Bidzińska, Anna, Samouëlian, Vanessa, Barretina-Ginesta, Maria-Pilar, Vulsteke, Christof, Lai, Chyong-Huey, Pothuri, Bhavana, Zhang, Yu, Magallanes-Maciel, Manuel, Amit, Amnon, Guarneri, Valentina, Zagouri, Flora, Bell, Maria, Welz, Julia, Eminowicz, Gemma, Hruda, Martin, J Willmott, Lyndsay, Lichfield, Jasmine, Wang, Wei, Orlowski, Robert, Aktan, Gursel, Gladieff, Laurence, Van Gorp, Toon

“…Mismatch repair-deficient (dMMR) endometrial cancer is an inflamed phenotype with poor outcomes when meeting high-risk criteria and limited treatment options…”
Get full text

Implementing HRD Testing in Routine Clinical Practice on Patients with Primary High-Grade Advanced Ovarian Cancer by Heitz, Florian, Ataseven, Beyhan, Staniczok, Claudia, Denkert, Carsten, Rhiem, Kerstin, Hahnen, Eric, Heikaus, Sebastian, Moubarak, Malak, Welz, Julia, Dagres, Timoleon, Vrentas, Vasilios, Bommert, Mareike, Schneider, Stephanie, Concin, Nicole, Harter, Philipp

“…The chemotherapy backbone for patients with high-grade advanced epithelial ovarian cancer (HG-AOC) is carboplatin and paclitaxel followed by a maintenance…”
Get full text

A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer (305) by Lee, Chee, Gebski, Val, Francis, Katherine, Grenier, Julien, Welz, Julia, Mosconi, Anna Maria, Rubio-Perez, Maria Jesús, Grimm, Christoph, Matsumoto, Takashi, Vergote, Ignace, Colombo, Nicoletta, Mirza, Mansoor Raza, FOLLANA, Philippe, de Gregorio, Nikolaus, Zamagni, Claudio, García-García, Yolanda, Meunier, Jérôme, Pujade-Lauraine, Eric, Friedlander, Michael, Ray-Coquard, Isabelle

Get full text

Diagnosis and management of isolated serous tubal intraepithelial carcinoma: A qualitative focus group study by Negri, Serena, Fisch, Charlotte, Hullu, Joanne A., Bommel, Majke, Simons, Michiel, Bogaerts, Joep, Apperloo, Mirjam J.A., Baiocchi, Glauco, Bakker, Janine L., Bart, Joost, Beekhuizen, Heleen J., Bernardini, Marcus Q., Boere, Ingrid, Bulten, Johan, Chen, Lee‐may, Chrzan, Alicja, Dørum, Anne, Ewing‐Graham, Patricia C., Ferrero, Annamaria, Flöter Rådestad, Angelique, Fruscio, Robert, Gaarenstroom, Katja N., Garcia, Christine, Harter, Philipp, Hoogstad‐van Evert, Janneke S., Iaco, Pierandrea, Klooster, Astrid, Kooreman, Loes F.S., Jacobsen, Michelle, Kruse, Arnold‐Jan, Kwon, Janice S., Lawson, Barrett C., Lax, Sigurd F., Lonkhuijzen, Luc R.C.W., Lu, Karen H., Manchanda, Ranjit, Marchetti, Claudia, McCluggage, W. Glenn, McNally, Orla M., Mourits, Marian J.E., Nicum, Shibani, Norquist, Barbara M., Perrone, Anna Myriam, Piek, Jurgen M.J., Polastro, Laura, Polee, Marco B., Rabban, Joseph T., Reesink, Nathalie, Reyes Oliver Pérez, Maria, Roes, Eva‐Maria, Rychlik, Agnieszka, Shih, Ie‐Ming, Soong, T. Rinda, Speiser, Paul, Stone, Rebecca L., Tamussino, Karl, Tognon, Germana, Tuninetti, Valentina, Valabrega, Giorgio, Vos, M. Caroline, Welz, Julia, Zizioli, Valentina, Hermens, Rosella P. M. G., Steenbeek, Miranda P.

“…Objective A Serous Tubal Intraepithelial Carcinoma (STIC) without concomitant invasive carcinoma is occasionally identified and associated with a high risk of…”
Get full text

Self-reported physical, mental, and reproductive sequelae after treatment of abnormally invasive placenta: a single-center observational study by Welz, Julia, Keyver-Paik, Mignon-Denise, Gembruch, Ulrich, Merz, Waltraut Maria

“…Objective To analyze the types of treatment of abnormally invasive placenta (AIP) and to investigate the self-reported physical and mental short- and long-term…”
Get full text

Incidence and Prognostic Impact of Deleterious Germline Mutations in Primary Advanced Ovarian Carcinoma Patients by Imterat, Majdi, Harter, Philipp, Rhiem, Kerstin, Heitz, Florian, Schneider, Stephanie, Concin, Nicole, Moubarak, Malak, Welz, Julia, Vrentas, Vasileios, Traut, Alexander, Hahnen, Eric, Schmutzler, Rita, du Bois, Andreas, Ataseven, Beyhan

“…Data on deleterious variants in genes other than remain limited. A retrospective cohort study was performed, including primary OC cases with TruRisk germline…”
Get full text

Treatment strategies in patients with gynecological sarcoma: Results of the prospective intergroup real-world registry for gynecological sarcoma in Germany (REGSA-NOGGO RU1) by Roser, Eva, Harter, Philipp, Zocholl, Dario, Denschlag, Dominik, Chekerov, Radoslav, Wimberger, Pauline, Kurzeder, Christian, Hasenburg, Annette, Muallem, Mustafa-Zelal, Mustea, Alexander, Emons, Guenter, Zeimet, A G, Beck, Felix, Arndt, Tjadina, Brucker, Sara Y, Kommoss, Stefan, Heitz, Florian, Welz, Julia, Egger, Eva-Katharina, Kalder, Matthias, Buderath, Paul, Klar, Maximilian, Marth, Christian, Ulrich, Uwe Andreas, Weigel, Michael, Traub, Lea, Anthuber, Christoph, Strauss, Hans, Hanker, Lars, Link, Theresa, Kubiak, Karol, Melekian, Badrig, Hornung, Daniela, Pölcher, Martin, Lampe, Bjoern, Krauß, Thomas, Keilholz, Ulrich, Flörcken, Anne, Pietzner, Klaus, Sehouli, Jalid

“…Gynecological sarcomas account for 3% of all gynecological malignancies and are associated with a poor prognosis. Due to the rarity and heterogeneity of…”
Get more information

Tamoxifen induces resistance to activated protein C by Rühl, Heiko, Schröder, Lars, Müller, Jens, Fimmers, Rolf, Sukhitashvili, Shorena, Welz, Julia, Kuhn, Walther C, Oldenburg, Johannes, Rudlowski, Christian, Pötzsch, Bernd

“…Abstract Introduction The estrogen antagonist tamoxifen (TAM) increases the thrombotic risk similar to estrogen containing oral contraceptives (OC). In OC…”
Get full text

Impact of Hormone-Associated Resistance to Activated Protein C on the Thrombotic Potential of Oral Contraceptives: A Prospective Observational Study: e105007 by Ruehl, Heiko, Schroder, Lars, Mueller, Jens, Sukhitashvili, Shorena, Welz, Julia, Kuhn, Walther C, Oldenburg, Johannes, Rudlowski, Christian, Potzsch, Bernd

“…Introduction The increased thrombotic risk of oral contraceptives (OC) has been attributed to various alterations of the hemostatic system, including acquired…”
Get full text